Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VCYT
VERACYTE, INC.
NASDAQ
$43.34
▼ DOWN 4.22% (-1.91)

KEY STATISTICS

Market Cap$3.46 B
52w High$60.91
52w Low$29.38
Dividend Yield—
Frequency—
P/E21.67
Volume1.68M
Shares Out.79.79M

COMPANY

LEADERSHIP

Marc A. Stapley
CHIEF EXECUTIVE
Marc A. Stapley

COMPENSATION 2026

Salary$700,000
Stock Awards$5,890,877
Incentive Plan Pay$826,000
All Other Comp.$5,000
Total$7,421,877

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 29, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
755

PRICE TARGET

Target High$69.00
Target Low$44.00
Target Median$54.00
Target Consensus$55.57

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$147.15M
NOV
3
TUE

PRICE

$43.34 ▼ DOWN 4.22% (−$1.91)
$43.50$44.25$45.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM43.34

About Veracyte, Inc.

https://www.veracyte.com ↗

Veracyte, Inc. is a global diagnostics company offering genomic tests for cancer and lung disease diagnosis and management, with collaborations including Johnson & Johnson.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT VERACYTE, INC. IS KNOWN FOR

Decipher Prostate Genomic Classifier
Decipher Prostate Genomic Classifier

The Decipher Prostate Genomic Classifier is a 22-gene test that assesses prostate tumor aggressiveness and metastasis risk to guide treatment decisions, now expanded to include metastatic prostate cancer.

COMPETITORS

COMPETITOR
GH COMPARE
MDXH COMPARE
MYGN COMPARE
NTRA COMPARE
OPK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Testing$127.76M $135.83M ▲$135.09M ▼$145.66M ▲
Product$3.3M $3.85M ▲$3.68M ▼$3.86M ▲
Biopharmaceutical And Other$1.09M $686K ▼$301K ▼$802K ▲

Revenue by Geography

MapREGIONQ4-2023Q4-2024
UNITED STATES$334.52M $423.54M ▲
NonUS$26.53M $22.23M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
247
LISTED HERE
26
RANKED BY POSITION SIZE
XUU.TO
0.00% · 4.9M
VTS.AX
0.01% · 2.5M
XBI
0.60% · 1.6M
FBT
2.41% · 1.6M
ARKK
0.70% · 1.0M
AIAI.L
1.24% · 583.5K
SCHA
0.07% · 378.7K
DFAT
0.11% · 362.2K
PBE
2.31% · 208.2K
JSMD
0.70% · 172.0K
PSC
0.24% · 149.3K
FESM
0.09% · 130.6K
THNQ
1.23% · 124.7K
TMAT
1.34% · 84.4K
NUSC
0.26% · 84.2K
XRSG.L
0.12% · 73.9K
LABU
0.41% · 57.8K
GNOM
2.63% · 55.5K
GSC
0.78% · 48.5K
WSCSRI.SW
0.13% · 24.6K
BBSC
0.13% · 22.1K
ETHO
0.39% · 17.8K
TQSM.TO
0.09% · 15.6K
TPSC
0.17% · 15.3K
ISMD
0.15% · 11.7K
EZM
0.05% · 10.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.32%
HOLDERS
499
TOP 12 OF 499 · RANKED BY POSITION SIZE
Blackrock, Inc.
13.5M sh · $792.06M
Vanguard Group Inc
8.5M sh · $291.95M
Blackrock Inc.
7.8M sh · $168.88M
Fmr LLC
7.8M sh · $250.07M
Artisan Partners Limited Partnership
7.4M sh · $253.03M
State Street Corp
5.0M sh · $162.45M
Ark Investment Management LLC
4.5M sh · $153.31M
Wellington Management Group Llp
3.4M sh · $115.8M
Dimensional Fund Advisors LP
3.1M sh · $107.04M
Arrowmark Colorado Holdings LLC
2.5M sh · $87.4M
First Trust Advisors LP
2.5M sh · $147.29M
Geode Capital Management, LLC
2.1M sh · $123.59M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity4
Return On Assets5
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-02-18
 Josh Gottheimer
Josh Gottheimer
Purchase
2023-10-16
 Daniel Goldman
Daniel Goldman
Sale
2023-04-10

INSIDER TRADES

★
DIRECTOR
EASTHAM KARIN
Sale · 3.2K shares
2026-06-18
★
DIRECTOR
EASTHAM KARIN
Sale · 529 shares
2026-06-18
★
DIRECTOR
EASTHAM KARIN
Purchase · 5.3K shares
2026-06-11
★
DIRECTOR
JONES EVAN/ FA
Purchase · 5.3K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
UNDERWEIGHT 1
HOLD 1
7 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Stephens & Co. OVERWEIGHT Morgan Stanley UNDERWEIGHT Canaccord Genuity HOLD Needham BUY Guggenheim BUY UBS BUY

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
KNSA$78.08COMPARE
ADPT$25.19COMPARE
IDYA$40.11COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE
ZLAB$26.08COMPARE